Hemorrhage Clinical Trial
Official title:
Correlation Between Platelet Function Analyzer-100 Testing and Bleeding Events After Percutaneous Kidney Biopsy
Kidney biopsy represents the criterion standard to obtain information on diagnosis and prognosis of renal dysfunctions . Many patients with kidney disease have a predisposition to bleed, especially when they undergo an invasive procedure such as renal biopsy. The predominant factor is abnormal platelet function. Therefore, the aim of this study is to evaluate whether the platelet function analyzer (PFA-100), a very reliable test to investigate primary hemostasis, can be useful in predicting the risk of bleeding complications in patients undergoing renal biopsy.
Kidney biopsy frequently is used to investigate the cause of suspected renal parenchymal
disease. Although kidney biopsy may provide important diagnostic information and guide
therapeutic decisions, the benefits must be weighed against the potential harms of biopsy.
Bleeding is one of the most feared risks from a renal biopsy.
The technique has significantly evolved because of the introduction of real-time ultrasound
guidance and use an automated spring-loaded biopsy device. As a consequence, the general
safety and complication rate of the procedure has substantially improved. Post biopsy
bleeding (hematoma and hematuria) is the primary complication of renal biopsies. However,
most of the perirenal hematomas are minor and without clinical significance, and major
complications are infrequent.
To minimize bleeding risk, we used the following prebiopsy parameters as a guide: prothrombin
time (PT), activated partial thromboplastin time (aPTT), platelet count, age, sex, glomerular
filtration rate and blood pressure. Antiaggregant and anticoagulant were stopped for 7 -10
days before biopsy. The Ivy bleeding time (BT) was performed.
Although an specific lancet is used to deliver a relatively standardized incision on the
patient's forearm, the Ivy bleeding time technique is patient and operator-dependent. Skin
thickness varies not only with age, but also with a number of other factors, such as
nutritional status. For these reasons was developed the platelet function analyzer, PFA-100.
This test assess primary haemostasis in vitro using citrated whole blood. The device
simulates in vivo haemostatic plug formation under high shear flow by measuring the time
required to occlude (closure time, CT) a collagen/epinephrine (Coll-EPI) or collagen/ADP
(Coll-ADP)-coated aperture inserted in a plastic membrane. PFA-100 is more sensitive than BT
to abnormalities of primary haemostasis.
The objective of this study is to demonstrate whether an abnormal PFA-100 can predict
bleeding events after percutaneous kidney biopsy.
The present cohort includes 250 all adult patients who underwent percutaneous renal biopsy of
native kidney in the Department of Emergency and Organ Transplantation, the University of
Bari, Italy, from January 2017 to December 2018. Transplant kidney biopsies were excluded
from this study. Three experienced nephrologists performed all the biopsies.
Participation included clinical data collection, serial blood and urine sampling before and
after the procedure. Kidney ultrasound was performed in all patients before the procedure.
The following data were collected for all patients:
- Variables pre-biopsy:
- baseline demographics (age, gender);
- indication for renal biopsy [urinary abnormalities (i.e., proteinuria and
haematuria), and/or recurrent macrohaematuria and/or nephrotic syndrome and/or
nephritic syndrome and/or alteration of renal function and/or acute renal failure];
- baseline systolic and diastolic blood pressure;
- which kidney was biopsied;
- baseline serum creatinine, azotaemia and glomerular filtration rate;
- baseline haemoglobin and platelet count;
- baseline coagulation parameters (prothrombin time, partial thromboplastin time,
bleeding time);
- baseline urinary protein excretion;
- body mass index.
- Variables during-biopsy:
- administration of DDAVP;
- number of passes;
- number of renal biopsy samples;
- the position of the patient during kidney biopsy [prone position or supine
anterolateral position (SALP)];
- Variables post-biopsy:
- hemoglobin;
- post-biopsy bleeding complications (gross hematuria, hematoma);
- if was necessary transfusion of blood products or an invasive procedure
(angiography and arterial embolization or surgery).
Evaluation of kidneys conditions were performed by ultrasound before the procedure in all
patients. Longitudinal and transverse size, corticomedullary differentiation shape, location
and related structures of the kidney were assessed using ultrasound and blood flow of the
kidneys were assessed using a color-flow Doppler signal.
All biopsies were performed using real-time ultrasound-fixed guidance by a nephrologist with
assistance from an expert in renal ultrasonography. A 16-gauge automated spring-loaded gun
was used for the biopsy. A pathologist promptly examined the biopsy specimen under alight
microscope to confirm that adequate renal tissue was available for further pathological
evaluations. 1-deamino-8-D-arginine vasopressin (DDAVP) was administered to all patients who
had not contraindication.
After the procedure, patients were invited to rest in bed on their backs for a 24-hour
observation time. Meantime, clinical evaluation (gross haematuria, flank pain, hypotension)
was performed to identify a bleeding complications. Ultrasound evaluation was performed for
all patients after 24 hours from percutaneous renal biopsy to exclude a presence of
complication, as hematoma and arteriovenous fistula Post biopsy bleeding complications were
categorized as either minor or major. Minor bleeding complications included gross haematuria
and/or subcapsular perinephric hematoma (<5cm diameter) that spontaneously resolved without
need for further intervention. Major complications were defined as those that required an
intervention for resolution, either the transfusion of blood products or an invasive
procedure (angiography, surgery), and those that led to acute renal obstruction or failure,
septicaemia, or death. The size of post biopsy hematoma (surface area) was defined as the
product of the longest and the shortest diameters on the two-dimensional sonographic
pictures.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02815670 -
Reversal Dabigatran Anticoagulant Effect With Idarucizumab
|
Phase 3 | |
Completed |
NCT04588350 -
Clinical Investigation Evaluating a New Autotransfusion Device in Cardiac Surgery
|
N/A | |
Recruiting |
NCT02972385 -
Pharmacogenomics of Warfarin in Hispanics and Latinos
|
||
Completed |
NCT02554006 -
Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings
|
N/A | |
Completed |
NCT02569606 -
Transfusion and Coagulation Management in Trauma Patients After the Introduction of a Coagulation Algorithm
|
||
Recruiting |
NCT02446730 -
Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome
|
Phase 4 | |
Completed |
NCT01935427 -
Comparison of Compensatory Reserve Index to Intravascular Volume Change and Stroke Volume
|
N/A | |
Completed |
NCT01955720 -
Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran
|
Phase 1 | |
Recruiting |
NCT01709786 -
Non-Invasive Hemoglobin Monitoring in Patients With Hemorrhage
|
N/A | |
Completed |
NCT01210417 -
Trauma Heart to Arm Time
|
N/A | |
Completed |
NCT01191554 -
Dose-ranging Study of Tranexamic Acid in Valve Surgery
|
N/A | |
Completed |
NCT01136590 -
Multicenter, Randomized Placebo-controlled Clinical Trial to Evaluate the Effect of Perioperative Use of Tranexamic Acid on Transfusion Requirements and Surgical Bleeding in Major Spine Surgery
|
Phase 4 | |
Completed |
NCT01085006 -
The Effect of Tranexamic Acid on Postpartum Hemorrhage During and After Cesarean Delivery
|
Phase 1/Phase 2 | |
Completed |
NCT00700141 -
Non-Interventional Study About Treatment of Hemorrhages in Thyroid Surgery With TachoSil®
|
N/A | |
Completed |
NCT00375466 -
Tranexamic Acid, Hemorrhage and Transfusions After Combined Aortic Valve Replacement and Coronary Artery Bypass Surgery.
|
N/A | |
Completed |
NCT00479362 -
Anticoagulant Therapy During Pacemaker Implantation
|
Phase 4 | |
Completed |
NCT00147420 -
RCT of Zhi Byed 11 (ZB11) Versus Misoprostol in Tibet
|
N/A | |
Recruiting |
NCT05945680 -
Tranexamic Acid in Breast Esthetic Surgery.
|
Phase 4 | |
Completed |
NCT03273322 -
Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure
|
Phase 2/Phase 3 | |
Withdrawn |
NCT05672407 -
The Role of Local Tranexamic Acid on Periorbital Oculoplastic Surgery
|
Phase 4 |